CanSense-CRC
Research type
Research Study
Full title
Phase two retrospective observational single blind multi-site performance evaluation trial of serum Raman spectroscopy in the assessment of a symptomatic primary care population with lower gastrointestinal symptoms.
IRAS ID
295736
Contact name
Dean Harris
Contact email
Sponsor organisation
Swansea Bay University Health Board
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
Background
Bowel cancer is one of the most common cancers worldwide and a leading cause of cancer related deaths. Early detection is potentially curative but symptoms of bowel cancer are non-specific so it is a challenge for GPs to diagnose early. Many
symptomatic patients are referred for a colonoscopy, which is costly and unpleasant. Most colonoscopies prove to be normal, but the large number of referrals delays urgent cases being seen. There is a real need for faster detection methods.
CanSense Group is a UK based university spin out company focussed on improving cancer outcomes. Our novel test combines laser-based blood sample analysis (spectroscopy) and artificial intelligence classification for cancer detection. Early results indicate that the blood test is highly accurate at detecting bowel cancer and pre-cancerous polyps.
Design/ Methods
The aim of this research is to advance technology readiness for future adoption into the NHS. This project will migrate our test from current academic research instrumentation to a scalable and commercially viable platform which retains the required conformity for an accurate diagnostic bowel cancer test. The project will incorporate an optimised artificial intelligence (AI) algorithm to interpret and learn from the results it processes. The project will advance by testing the effectiveness and safety aspects of the AI algorithm. Preparedness for future regulatory approval and full clinical trials on the basis of accredited practices and processes will help accelerate adoption.
Patient/ public involvement
Patient involvement from the project’s inception has shaped and affirmed the need for an acceptable and accessible cancer blood test in primary care. PPI partners on the project management team will help design, deliver and disseminate in preparedness for market adoption.
Dissemination
Project findings will be shared through numerous government, academic, NHS and PPI partners, across social media, publications and news releases to help achieve NHS adoption for patient benefit.REC name
N/A
REC reference
N/A